Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | RAD52 | P43351 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | NSD2 | O96028 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6438255 | 0.89 | TOP2B (0.53) | MAPTMAPK1EGFRSMN1; SMN2L3MBTL1 | |
| SCHEMBL7122672 | 0.85 | MAPT (0.53) | MAPTMAPK1EGFRSMN1; SMN2L3MBTL1 | |
| SCHEMBL1906212 | 0.81 | MAPT (0.56) | MAPTMAPK1EGFRSMN1; SMN2L3MBTL1 | |
| SCHEMBL10622223 | 0.81 | MEN1 (0.53) | MAPTMAPK1EGFRSMN1; SMN2L3MBTL1 | |
| SCHEMBL7156586 | 0.79 | MAPT (0.66) | MAPTMAPK1EGFRSMN1; SMN2L3MBTL1 | |
| SCHEMBL13995639 | 0.79 | MAPT (0.65) | MAPTMAPK1EGFRSMN1; SMN2L3MBTL1 | |
| SCHEMBL4732627 | 0.76 | MEN1 (0.72) | MAPTMAPK1EGFRSMN1; SMN2L3MBTL1 | |
| SCHEMBL126055 | 0.76 | MAPT (0.59) | MAPTMAPK1EGFRSMN1; SMN2L3MBTL1 | |
| SCHEMBL8053208 | 0.76 | MAPT (0.66) | MAPTMAPK1EGFRSMN1; SMN2L3MBTL1 | |
| SCHEMBL6063381 | 0.76 | NSD2 (0.49) | MAPTMAPK1EGFRSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130272-A1 | Anthracene derivatives as anti-cancer agents | BTG INTERNATIONAL LIMITED (GB) | 2003-07-10 | — | — | US | disclosed |
| EP-1244624-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001044190-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
| US-5935969-A | Pyrido-thiopyrandoinazoles with antitumor activity | UNIVERSITY OF VERMONT (US) | 1999-08-10 | — | — | US | disclosed |
| EP-0450021-B1 | ANTI-CANCER COMPOUNDS | BRITISH TECH GROUP (GB) | 1994-02-02 | — | — | EP | disclosed |
| US-5132327-A | ANTI-CANCER COMPOUNDS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1992-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130272-A1 | Anthracene derivatives as anti-cancer agents | TOP2B, TOP1, TOP2A | MAPT 4884/4885MAPK1 3848/4885EGFR 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.